| Basics |
Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. The company is engaged in the development and commercialization of therapies for people with rare debilitating diseases, chronic neuromuscular and neurological diseases.
|
| IPO Date: |
October 5, 2001 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$3.15B |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.14 | 3.27%
|
| Avg Daily Range (30 D): |
$0.38 | 1.54%
|
| Avg Daily Range (90 D): |
$0.40 | 1.70%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.83M |
| Avg Daily Volume (30 D): |
.95M |
| Avg Daily Volume (90 D): |
.95M |
| Trade Size |
| Avg Trade Size (Sh.): |
154 |
| Avg Trade Size (Sh.) (30 D): |
56 |
| Avg Trade Size (Sh.) (90 D): |
57 |
| Institutional Trades |
| Total Inst.Trades: |
2,052 |
| Avg Inst. Trade: |
$2.68M |
| Avg Inst. Trade (30 D): |
$2.93M |
| Avg Inst. Trade (90 D): |
$3.15M |
| Avg Inst. Trade Volume: |
.22M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$3.37M |
| Avg Closing Trade (30 D): |
$4.39M |
| Avg Closing Trade (90 D): |
$5.04M |
| Avg Closing Volume: |
277.04K |
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$1.65
|
$.47
|
$.46
|
|
Diluted EPS
|
$1.57
|
$.45
|
$.44
|
|
Revenue
|
$ 534.65M
|
$ 141.42M
|
$ 141.82M
|
|
Gross Profit
|
$ 460.41M
|
$ 123.51M
|
$ 120.18M
|
|
Net Income / Loss
|
$ 197.35M
|
$ 56.74M
|
$ 55.94M
|
|
Operating Income / Loss
|
$ 231.37M
|
$ 63.37M
|
$ 62.84M
|
|
Cost of Revenue
|
$ 74.24M
|
$ 17.91M
|
$ 21.64M
|
|
Net Cash Flow
|
$ 207.14M
|
$ M
|
$ 75.22M
|
|
PE Ratio
|
0.00
|
|
|
|
|
|
